Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Jee Soon Kim 3 Articles
The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence
Jee Soon Kim, Youn Soo Lee, Min Jung Jung, Yong Kil Hong
J Pathol Transl Med. 2016;50(6):419-425.   Published online October 6, 2016
DOI: https://doi.org/10.4132/jptm.2016.06.30
  • 7,433 View
  • 228 Download
  • 17 Web of Science
  • 17 Crossref
AbstractAbstract PDF
Background
The 2004 World Health Organization classification introduced atypical pituitary adenoma (aPA), which was equivocally defined as invasion with increased mitotic activity that had a Ki-67 labeling index (LI) greater than 3%, and extensive p53 immunoreactivity. However, aPAs that exhibit all of these features are rare and the predictive value for recurrence in pituitary adenomas (PAs) remains uncertain. Thus, we sought to characterize pathological features of PAs that correlated with recurrence.
Methods
One hundred and sixty-seven cases of surgically resected PA or aPA were retrieved from 2011 to 2013 in Seoul St. Mary’s Hospital. Among them, 28 cases were confirmed to be recurrent, based on pathologic or radiologic examination. The pathologic characteristics including mitosis, invasion, Ki-67 LI and p53 immunoreactivity were analyzed in relation to recurrence.
Results
Analysis of the pathologic features indicated that only Ki-67 LI over 3% was significantly associated with tumor recurrence (p = .02). The cases with at least one pathologic feature showed significantly higher recurrence rates (p < .01). Analysis indicated that cases with two pathologic features, Ki-67 LI over 3% and extensive p53 immunoreactivity 20% or more, were significantly associated with tumor recurrence (p < .01).
Conclusions
Based on these results, PA tumor recurrence can be predicted by using mitosis, invasion, Ki-67 LI (3%), or extensive p53 immunoreactivity (≥ 20%). Assessment of these features is recommended for PA diagnosis for more accurate prediction of recurrence.

Citations

Citations to this article as recorded by  
  • The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
    Roxana-Ioana Dumitriu-Stan, Iulia-Florentina Burcea, Valeria Nicoleta Nastase, Raluca Amalia Ceaușu, Anda Dumitrascu, Laurentiu Catalin Cocosila, Alexandra Bastian, Sabina Zurac, Marius Raica, Catalina Poiana
    International Journal of Molecular Sciences.2023; 24(22): 16162.     CrossRef
  • Ki-67/MIB-1 and Recurrence in Pituitary Adenoma
    Kent Tadokoro, Colten Wolf, Joseph Toth, Cara Joyce, Meharvan Singh, Anand Germanwala, Chirag Patel
    Journal of Neurological Surgery Part B: Skull Base.2022; 83(S 02): e580.     CrossRef
  • Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas
    Su Jung Kum, Hye Won Lee, Soon Gu Kim, Hyungsik Park, Ilseon Hwang, Sang Pyo Kim
    Journal of Pathology and Translational Medicine.2022; 56(1): 22.     CrossRef
  • A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
    Yu Zhang, Yuqi Luo, Xin Kong, Tao Wan, Yunling Long, Jun Ma
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors
    Anne-Laure Bernat, Pénélope Troude, Stefano Maria Priola, Ahmad Elsawy, Faisal Farrash, Ozgur Mete, Shereen Ezzat, Sylvia L. Asa, John De Almeida, Allan Vescan, Eric Monteiro, Joao Paulo Almeida, Gelareh Mohammed Zadeh, Fred Gentili
    World Neurosurgery.2021; 146: e341.     CrossRef
  • A Nomogram for Preoperatively Predicting the Ki-67 Index of a Pituitary Tumor: A Retrospective Cohort Study
    Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Feng Yuan, Zixiang Cong, Chiyuan Ma
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas
    Carolina Carrillo-Najar, Daniel Rembao-Bojórquez, Martha L. Tena-Suck, Sergio Zavala-Vega, Noemí Gelista-Herrera, Miguel A. Ramos-Peek, Juan L. Gómez-Amador, Febe Cazares-Raga, Fidel de la Cruz Hernández-Hernández, Alma Ortiz-Plata
    Diagnostics.2021; 11(2): 330.     CrossRef
  • Prediction of recurrence in solid nonfunctioning pituitary macroadenomas: additional benefits of diffusion-weighted MR imaging
    Ching-Chung Ko, Tai-Yuan Chen, Sher-Wei Lim, Yu-Ting Kuo, Te-Chang Wu, Jeon-Hor Chen
    Journal of Neurosurgery.2020; 132(2): 351.     CrossRef
  • Pituitary tumors: epidemiology and clinical presentation spectrum
    Marta Araujo-Castro, Víctor Rodríguez Berrocal, Eider Pascual-Corrales
    Hormones.2020; 19(2): 145.     CrossRef
  • Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature
    E. Guadagno, E. D’Avella, P. Cappabianca, A. Colao, M. Del Basso De Caro
    Journal of Endocrinological Investigation.2020; 43(10): 1429.     CrossRef
  • Study of Simple Immunohistochemical Cytocolorimetric Assay Application for More Accurate Assessment of Prognosis in Patients with Pituitary Adenomas
    Pavel V. Nikitin, Marina V. Ryzhova, Lyudmila V. Shishkina, Svetlana V. Shugay, Irina V. Zubova
    World Neurosurgery.2019; 122: e1047.     CrossRef
  • The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas
    Rovshan Hasanov, Berna İmge Aydoğan, Saba Kiremitçi, Esra Erden, Sevim Güllü
    Endocrine Pathology.2019; 30(1): 49.     CrossRef
  • Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors
    Jelena Maletkovic, Asmaa Dabbagh, Dongyun Zhang, Abdul Zahid, Marvin Bergsneider, Marilene B Wang, Michael Linetsky, Noriko Salamon, William H Yong, Harry V Vinters, Anthony P Heaney
    Journal of the Endocrine Society.2019; 3(10): 1931.     CrossRef
  • Atypical pituitary adenoma: a clinicopathologic case series
    Martin J. Rutkowski, Ryan M. Alward, Rebecca Chen, Jeffrey Wagner, Arman Jahangiri, Derek G. Southwell, Sandeep Kunwar, Lewis Blevins, Han Lee, Manish K. Aghi
    Journal of Neurosurgery.2018; 128(4): 1058.     CrossRef
  • Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients
    Julie Lelotte, Anne Mourin, Edward Fomekong, Alex Michotte, Christian Raftopoulos, Dominique Maiter
    European Journal of Endocrinology.2018; 178(3): 237.     CrossRef
  • Letter to the Editor. Atypical pituitary adenoma
    Lauren E. Rotman, T. Brooks Vaughan, James R. Hackney, Kristen O. Riley
    Journal of Neurosurgery.2018; 129(6): 1657.     CrossRef
  • Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies
    Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, Ashley Grossman
    Endocrine-Related Cancer.2017; 24(6): R239.     CrossRef
Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma
Woo Jin Oh, Arthur Minwoo Chung, Jee Soon Kim, Ji Heun Han, Sung Hoo Hong, Ji Yeol Lee, Yeong Jin Choi
J Pathol Transl Med. 2016;50(5):345-354.   Published online August 7, 2016
DOI: https://doi.org/10.4132/jptm.2016.06.14
  • 10,981 View
  • 316 Download
  • 25 Web of Science
  • 28 Crossref
AbstractAbstract PDF
Background
The pathologic distinction between high-grade prostate adenocarcinoma (PAC) involving the urinary bladder and high-grade urothelial carcinoma (UC) infiltrating the prostate can be difficult. However, making this distinction is clinically important because of the different treatment modalities for these two entities.
Methods
A total of 249 patient cases (PAC, 111 cases; UC, 138 cases) collected between June 1995 and July 2009 at Seoul St. Mary’s Hospital were studied. An immunohistochemical evaluation of prostatic markers (prostate-specific antigen [PSA], prostate-specific membrane antigen [PSMA], prostate acid phosphatase [PAP], P501s, NKX3.1, and α-methylacyl coenzyme A racemase [AMACR]) and urothelial markers (CK34βE12, p63, thrombomodulin, S100P, and GATA binding protein 3 [GATA3]) was performed using tissue microarrays from each tumor.
Results
The sensitivities of prostatic markers in PAC were 100% for PSA, 83.8% for PSMA, 91.9% for PAP, 93.7% for P501s, 88.3% for NKX 3.1, and 66.7% for AMACR. However, the urothelial markers CK34βE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively. The sensitivities of urothelial markers in UC were 75.4% for CK34βE12, 73.9% for p63, 45.7% for thrombomodulin, 22.5% for S100P, and 84.8% for GATA3. Conversely, the prostatic markers PSA, PSMA, PAP, P501s, NKX3.1, and AMACR were also positive in 9.4%, 0.7%, 18.8%, 0.7%, 0%, and 8.7% of UCs, respectively.
Conclusions
Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC. The optimal combination of prostatic and urothelial markers could improve the ability to differentiate PAC from UC pathologically.

Citations

Citations to this article as recorded by  
  • Unusual Perineal Metastasis in a Case of Prostate Cancer on 68Ga-PSMA-11 PET/CT
    Ritanshu Solanki, Bhagwant Rai Mittal, Rajender Kumar, Aravindh Sekar, Narender Kumar
    Clinical Nuclear Medicine.2024; 49(2): e73.     CrossRef
  • NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma
    Ansa Mehreen, Kiran G. Manjee, Divyangi Paralkar, Gladell P. Paner, Thanh Lan
    Advances in Anatomic Pathology.2024; 31(3): 202.     CrossRef
  • Clinical Management of Intraductal Carcinoma of the Prostate
    Gabriel Wasinger, Olivier Cussenot, Eva Compérat
    Cancers.2024; 16(9): 1650.     CrossRef
  • Metastatic prostate cancer presenting as a posterior mediastinal mass: A rare presentation
    Muhammad Haider, Arun Umesh Mahtani, Bachar Botrus, Foma Munoh Kenne, Madiha Fatima Master
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma
    Daeseon Yoo, Kyueng-Whan Min, Jung-Soo Pyo, Nae Yu Kim
    Medicina.2023; 59(8): 1452.     CrossRef
  • Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature
    Liang Liu, Fu-zhen Sun, Pan-ying Zhang, Yu Xiao, Xiao Yue, Dong-Ming Wang, Qiang Wang
    The Aging Male.2023;[Epub]     CrossRef
  • Expression of Gata Binding Protein 3 as a Prognostic Factor in Urogenital Lesions and Its Association With Morphology
    T Govardhan, Debahuti Mohapatra, Sujata Naik, Prateek Das, Pranita Mohanty, Ankita Pal
    Cureus.2023;[Epub]     CrossRef
  • Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component
    Simone de Brot, Jennifer Lothion‐Roy, Llorenç Grau‐Roma, Emily White, Franco Guscetti, Mark A. Rubin, Nigel P. Mongan
    Veterinary and Comparative Oncology.2022; 20(1): 38.     CrossRef
  • Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications
    Arsalan Tariq, Amy E. McCart Reed, Andrew Morton, Sima Porten, Ian Vela, Elizabeth D. Williams, John W. Yaxley, Peter C. Black, Matthew J. Roberts
    European Urology Focus.2022; 8(5): 1256.     CrossRef
  • Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors
    Haruto Nishida, Yoshihiko Kondo, Takahiro Kusaba, Hiroko Kadowaki, Tsutomu Daa
    Head and Neck Pathology.2022; 16(2): 427.     CrossRef
  • Weak NKX3.1 expression in a urothelial carcinoma: A diagnostic pitfall
    Maryam Abdo, Robert Hoyt, Ashley Highfill, Daniel Mettman
    Human Pathology Reports.2022; 27: 300599.     CrossRef
  • Gene of the month: NKX3.1
    Jon Griffin, Yuqing Chen, James W F Catto, Sherif El-Khamisy
    Journal of Clinical Pathology.2022; 75(6): 361.     CrossRef
  • Diagnostic Value of GATA3 and Uroplakin 3 in Differentiating Urothelial Carcinoma from Prostatic and Colorectal Carcinoma
    Maha Salama, Dina A. Khairy
    Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 514.     CrossRef
  • Diagnostic challenges for the distinction of high-grade prostatic adenocarcinoma and high-grade urothelial carcinoma of simultaneous occurrences - A literature review
    Shreyas Bhushan Jayade, Manana Jikurashvili
    GEORGIAN SCIENTISTS.2022;[Epub]     CrossRef
  • Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma
    Xiaoqi Lin, Qiuying Shi, Ximing J. Yang
    Human Pathology.2022; 130: 36.     CrossRef
  • Cutaneous Metastasis of Prostate Adenocarcinoma: A Rare Presentation of a Common Disease
    Alexander Dills, Okechukwu Obi, Kevin Bustos, Jesse Jiang, Shweta Gupta
    Journal of Investigative Medicine High Impact Case Reports.2021; 9: 232470962199076.     CrossRef
  • Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma
    Ewe Seng Ch’ng
    Scientific Reports.2021;[Epub]     CrossRef
  • Immunohistochemical analysis of thrombomodulin expression in myocardial tissue from autopsy cases of ischemic heart disease
    Takeshi Kondo, Motonori Takahashi, Gentaro Yamasaki, Marie Sugimoto, Azumi Kuse, Mai Morichika, Kanako Nakagawa, Makoto Sakurada, Migiwa Asano, Yasuhiro Ueno
    Legal Medicine.2021; 51: 101897.     CrossRef
  • Application and Pitfalls of Immunohistochemistry in Diagnosis of Challenging Genitourinary Cases
    Jenny Ross, Guangyuan Li, Ximing J. Yang
    Archives of Pathology & Laboratory Medicine.2020; 144(3): 290.     CrossRef
  • New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers
    Karin Ried, Tasnuva Tamanna, Sonja Matthews, Peter Eng, Avni Sali
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • An Unlikely Culprit: Gastric Metastasis from Primary Prostatic Adenocarcinoma
    Eric Omar Then, Spoorthi Nutakki, Andrew Ofosu, Saad Saleem, Vijay Gayam, Tagore Sunkara, Vinaya Gaduputi
    Journal of Gastrointestinal Cancer.2020; 51(3): 1081.     CrossRef
  • MRI of prostatic urethral mucinous urothelial carcinoma: Expanding the differential diagnosis for T2 hyperintense prostatic masses
    Neel Patel, Bryan R. Foster, Elena K. Korngold, Kyle Jensen, Kevin R. Turner, Fergus V. Coakley
    Clinical Imaging.2020; 68: 68.     CrossRef
  • Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review
    Francesca Sanguedolce, Davide Russo, Vito Mancini, Oscar Selvaggio, Beppe Calò, Giuseppe Carrieri, Luigi Cormio
    International Journal of Surgical Pathology.2019; 27(2): 120.     CrossRef
  • A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy
    Darren J. Bryk, Kenneth W. Angermeier, Eric A. Klein
    Urology.2019; 129: e4.     CrossRef
  • The Homeodomain Transcription Factor NKX3.1 Modulates Bladder Outlet Obstruction Induced Fibrosis in Mice
    Mehul S. Patel, Diana K. Bowen, Nicholas M. Tassone, Andrew D. Gould, Kirsten S. Kochan, Paula R. Firmiss, Natalie A. Kukulka, Megan Y. Devine, Belinda Li, Edward M. Gong, Robert W. Dettman
    Frontiers in Pediatrics.2019;[Epub]     CrossRef
  • Cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy
    Morgan L. Cowan, Christopher J. VandenBussche
    Cancer Cytopathology.2018; 126(S8): 724.     CrossRef
  • Glandular Tumors of the Urachus and Urinary Bladder: A Practical Overview of a Broad Differential Diagnosis
    Alexander S. Taylor, Rohit Mehra, Aaron M. Udager
    Archives of Pathology & Laboratory Medicine.2018; 142(10): 1164.     CrossRef
  • S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers
    Moushumi Suryavanshi, Julian Sanz-Ortega, Deepika Sirohi, Mukul K. Divatia, Chisato Ohe, Claudia Zampini, Daniel Luthringer, Steven C. Smith, Mahul B. Amin
    Advances in Anatomic Pathology.2017; 24(3): 151.     CrossRef
Primary Neurilemmoma of the Thyroid Gland Clinically Mimicking Malignant Thyroid Nodule
Young Sub Lee, Jee Soon Kim, Arthur Minwoo Chung, Woo Chan Park, Tae-Jung Kim
J Pathol Transl Med. 2016;50(2):168-171.   Published online October 26, 2015
DOI: https://doi.org/10.4132/jptm.2015.08.26
  • 7,704 View
  • 67 Download
  • 3 Crossref
PDF

Citations

Citations to this article as recorded by  
  • A Case of Intra-thyroidal Schwannoma Diagnosed by Preoperative Core Needle Biopsy
    Dong Gyu Choi, Young-Ok Kim, Min Jung Jung, Hyoung Shin Lee
    Korean Society for Head and Neck Oncology.2023; 39(1): 37.     CrossRef
  • Multimodal ultrasound imaging of primary thyroid schwannoma
    Hai Na Zhao, Bu Yun Ma, Feng Yan, Yu Lan Peng
    Medicine.2021; 100(16): e25517.     CrossRef
  • A Case of Anterior Cervical Intramuscular Schwannoma in the Strap Muscle
    Seul Gi Lee, Ho-Ryun Won, Bon Seok Koo, Jae Won Chang
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2021; 64(4): 263.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine